Global Factor IX Complex Drug Market Growth 2025-2031

The global Factor IX Complex Drug market size is predicted to grow from US$ 1128 million in 2025 to US$ 2243 million in 2031; it is expected to grow at a CAGR of 12.1% from 2025 to 2031.

Prothrombin complex concentrate (PCC), also known as factor IX complex, is a medication made up of blood clotting factors II, IX, and X. Some versions also contain factor VII. It is used to treat and prevent bleeding in hemophilia B if pure factor IX is not available.

The market factors is increasing prescription of anticoagulants, especially warfarin, as well as rising prevalence of bleeding disorders. Additionally, PCC offers various advantages over Fresh-frozen plasma and others, making it a more suitable option for life-threatening conditions. Apart from this, active government support for the use of 4-factor PCC products such as Kcentra and positive recommendations are anticipated to provide considerable momentum to the market.

LP Information, Inc. (LPI) ' newest research report, the “Factor IX Complex Drug Industry Forecast” looks at past sales and reviews total world Factor IX Complex Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Factor IX Complex Drug sales for 2025 through 2031. With Factor IX Complex Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Factor IX Complex Drug industry.

This Insight Report provides a comprehensive analysis of the global Factor IX Complex Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Factor IX Complex Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Factor IX Complex Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Factor IX Complex Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Factor IX Complex Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Factor IX Complex Drug market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Beriplex
Profilnine
Octaplex
Prothromplex
Cofact
Other

Segmentation by Application:
Hemophilia B
Acquired Coagulation Factor Deficiency

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
CSL Behring
Grifols
Octapharma
Prothya Biosolutions
Takeda

Key Questions Addressed in this Report

What is the 10-year outlook for the global Factor IX Complex Drug market?

What factors are driving Factor IX Complex Drug market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Factor IX Complex Drug market opportunities vary by end market size?

How does Factor IX Complex Drug break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver. Show more